Scientific Sessions 2025  /  Updates in Diabetes Cardiovascular Outcome Trials  /  Will dual GIP and GLP1 receptor agonism SURPASS existing GLP1RAs?
Logo

American Heart Association

  30
  0

Final ID:

Will dual GIP and GLP1 receptor agonism SURPASS existing GLP1RAs?

  • Sattar, Naveed  ( UNIVERSITY OF GLASGOW , Glasgow , United Kingdom )
  • Nicholls, Stephen  ( Victorian Heart Hospital , Clayton , Victoria , Australia )
    • Author Disclosures:
    Naveed Sattar: DO have relevant financial relationships ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim:Past (completed) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Consultant:Roche:Active (exists now) ; Advisor:Pfizer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Metsera:Active (exists now) ; Consultant:Menarini-Ricerche:Active (exists now) ; Advisor:Hanmi Pharmaceuticals:Past (completed) ; Consultant:GlaxoSmithKline:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Carmot Therapeutics:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) | Stephen Nicholls: DO have relevant financial relationships ; Researcher:AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience:Active (exists now) ; Consultant:Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Scribe Therapeutics, Silence Therapeutics, CSL Seqirus and Vaxxinity:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Updates in Diabetes Cardiovascular Outcome Trials

Monday, 11/10/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Integrating lessons learned from diabetes CVOTs (old and new) into clinical care

Taub Pam, Gianos Eugenia

Once a PIONEER and now at the SOUL of the matter: cardiovascular outcomes with oral semaglutide

Mcguire Darren, Busui Rodica, Mulvagh Sharon, Inzucchi Silvio

More abstracts from these authors:
CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Nicholls Stephen

Will CETP inhibition PREVAIL in CVD prevention?

Nicholls Stephen

You have to be authorized to contact abstract author. Please, Login
Not Available